BeiGene, Ltd. (BGNE)
NASDAQ: BGNE · Real-Time Price · USD
176.50
+1.78 (1.02%)
At close: Dec 20, 2024, 4:00 PM
177.10
+0.60 (0.34%)
After-hours: Dec 20, 2024, 5:23 PM EST
BeiGene Employees
BeiGene had 10,600 employees as of December 31, 2023. The number of employees increased by 1,400 or 15.22% compared to the previous year.
Employees
10,600
Change (1Y)
1,400
Growth (1Y)
15.22%
Revenue / Employee
$316,161
Profits / Employee
-$80,606
Market Cap
18.75B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10,600 | 1,400 | 15.22% |
Dec 31, 2022 | 9,200 | 1,000 | 12.20% |
Dec 31, 2021 | 8,200 | 2,900 | 54.72% |
Dec 31, 2020 | 5,300 | 1,941 | 57.79% |
Dec 31, 2019 | 3,359 | 1,289 | 62.27% |
Dec 31, 2018 | 2,070 | 1,170 | 130.00% |
Dec 31, 2017 | 900 | 552 | 158.62% |
Dec 31, 2016 | 348 | 108 | 45.00% |
Dec 31, 2015 | 240 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Labcorp Holdings | 67,000 |
Quest Diagnostics | 48,000 |
ICON Public Limited Company | 41,100 |
STERIS | 18,179 |
Zimmer Biomet Holdings | 18,000 |
Molina Healthcare | 18,000 |
The Cooper Companies | 15,000 |
Illumina | 13,360 |
BGNE News
- 9 days ago - BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor - Business Wire
- 12 days ago - BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets - Business Wire
- 17 days ago - BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL - Business Wire
- 19 days ago - BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 - Business Wire
- 20 days ago - BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US - Seeking Alpha
- 24 days ago - European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer - Business Wire
- 25 days ago - BeiGene to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Labcorp CFO Glenn Eisenberg Announces Plans to Retire - PRNewsWire